Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 in Recurrent or Advanced Endometrial Cancer
NCT01307631Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2011
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206 in endometrial cancer (EC), sponsored by National Cancer Institute. Started Mar 2011; status: completed.
02
Drugs
MK-2206
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT01307631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01307631.